A First or Dominant Immunization. II. Induced Immunoglobulin Carries Transforming Growth Factor Beta and Suppresses Cytolytic T Cell Responses to Unrelated Alloantigens

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1993 Sep 1

PMID 8350058

Citations 18

Authors

R M Stach

D A Rowley

Affiliations

Soon will be listed here.

Abstract

Fresh sera from mice immunized by bearing an immunogenic tumor or by repeated injections of allogeneic spleen cells or xenogeneic erythrocytes powerfully suppress cytolytic T cell responses in one-way mixed lymphocyte cultures. Suppression is not antigen specific, though is mediated by immunoglobulin (Ig)G specific for the immunizing antigen. Suppression caused by IgG mimics that caused by active transforming growth factor beta (TGF-beta). IgG associates with or carries latent TGF-beta; however, suppression caused by the complex of IgG-TGF-beta requires macrophages (M phi), whereas active TGF-beta alone does not. Also, IgG dissociated from TGF-beta does not cause suppression, suggesting that M phi may take up Ig-TGF-beta, process the complex, and deliver active TGF-beta to lymphocytes. Indeed, suppression by immune serum was prevented by antibody to Fc receptors, by saturating Fc receptors with heterologous IgGs, and by antibodies against TGF-beta. The overall findings reveal a previously unrecognized regulatory circuit whereby IgG produced in response to one antigen nonspecifically downregulates cytolytic T lymphocyte responses to unrelated antigens. The findings introduce the intriguing possibility that TGF-beta delivered by IgG and processed by M phi may mediate important biological effects in processes such as wound healing, tumor growth, and some autoimmune diseases.

Citing Articles

Potential importance of B cells in aging and aging-associated neurodegenerative diseases.

Biragyn A, Aliseychik M, Rogaev E Semin Immunopathol. 2017; 39(3):283-294.

PMID: 28083646 PMC: 8011659. DOI: 10.1007/s00281-016-0615-8.

Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins.

Robertson I, Rifkin D Cold Spring Harb Perspect Biol. 2016; 8(6).

PMID: 27252363 PMC: 4888822. DOI: 10.1101/cshperspect.a021907.

IgG expression in human colorectal cancer and its relationship to cancer cell behaviors.

Niu N, Zhang J, Huang T, Sun Y, Chen Z, Yi W PLoS One. 2012; 7(11):e47362.

PMID: 23133595 PMC: 3486799. DOI: 10.1371/journal.pone.0047362.

A new paradigm for an old story: the role of regulatory B cells in cancer.

Biragyn A, Lee-Chang C Front Immunol. 2012; 3:206.

PMID: 22837759 PMC: 3401824. DOI: 10.3389/fimmu.2012.00206.

Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses.

Biragyn A, Longo D Semin Cancer Biol. 2012; 22(1):50-9.

PMID: 22257681 PMC: 3288709. DOI: 10.1016/j.semcancer.2012.01.005.

References

Kehrl J, Roberts A, Wakefield L, Jakowlew S, Sporn M, Fauci A . Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol. 1986; 137(12):3855-60. View

Sporn M, Roberts A, Wakefield L, Assoian R . Transforming growth factor-beta: biological function and chemical structure. Science. 1986; 233(4763):532-4. DOI: 10.1126/science.3487831. View

Espevik T, Figari I, Shalaby M, Lackides G, Lewis G, Shepard H . Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med. 1987; 166(2):571-6. PMC: 2189589. DOI: 10.1084/jem.166.2.571. View

Assoian R, Fleurdelys B, Stevenson H, Miller P, Madtes D, Raines E . Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci U S A. 1987; 84(17):6020-4. PMC: 298999. DOI: 10.1073/pnas.84.17.6020. View

Mustoe T, Pierce G, Thomason A, Gramates P, Sporn M, Deuel T . Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science. 1987; 237(4820):1333-6. DOI: 10.1126/science.2442813. View

Ranges G, Figari I, Espevik T, Palladino Jr M . Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med. 1987; 166(4):991-8. PMC: 2188710. DOI: 10.1084/jem.166.4.991. View

Blatti S, Foster D, Ranganathan G, Moses H, Getz M . Induction of fibronectin gene transcription and mRNA is a primary response to growth-factor stimulation of AKR-2B cells. Proc Natl Acad Sci U S A. 1988; 85(4):1119-23. PMC: 279717. DOI: 10.1073/pnas.85.4.1119. View

Keski-Oja J, Raghow R, Sawdey M, Loskutoff D, Postlethwaite A, Kang A . Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem. 1988; 263(7):3111-5. View

Coffey Jr R, Sipes N, Bascom C, Pennington C, Weissman B, Moses H . Growth modulation of mouse keratinocytes by transforming growth factors. Cancer Res. 1988; 48(6):1596-602. View

10.

Lyons R, Keski-Oja J, Moses H . Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol. 1988; 106(5):1659-65. PMC: 2115066. DOI: 10.1083/jcb.106.5.1659. View

11.

Czarniecki C, Chiu H, Wong G, McCabe S, Palladino M . Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol. 1988; 140(12):4217-23. View

12.

Clark D, Falbo M, Rowley R, Banwatt D . Active suppression of host-vs graft reaction in pregnant mice. IX. Soluble suppressor activity obtained from allopregnant mouse decidua that blocks the cytolytic effector response to IL-2 is related to transforming growth factor-beta. J Immunol. 1988; 141(11):3833-40. View

13.

Schwarz L, Gingras M, Goldberg G, Greenberg A, Wright J . Loss of growth factor dependence and conversion of transforming growth factor-beta 1 inhibition to stimulation in metastatic H-ras-transformed murine fibroblasts. Cancer Res. 1988; 48(24 Pt 1):6999-7003. View

14.

Danielpour D, Dart L, Flanders K, Roberts A, Sporn M . Immunodetection and quantitation of the two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) secreted by cells in culture. J Cell Physiol. 1989; 138(1):79-86. DOI: 10.1002/jcp.1041380112. View

15.

Miyazono K, Heldin C . Role for carbohydrate structures in TGF-beta 1 latency. Nature. 1989; 338(6211):158-60. DOI: 10.1038/338158a0. View

16.

Connor Jr T, Roberts A, Sporn M, Danielpour D, Dart L, Michels R . Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989; 83(5):1661-6. PMC: 303874. DOI: 10.1172/JCI114065. View

17.

Coffman R, Lebman D, Shrader B . Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J Exp Med. 1989; 170(3):1039-44. PMC: 2189449. DOI: 10.1084/jem.170.3.1039. View

18.

Sonoda E, Matsumoto R, Hitoshi Y, Ishii T, Sugimoto M, Araki S . Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J Exp Med. 1989; 170(4):1415-20. PMC: 2189486. DOI: 10.1084/jem.170.4.1415. View

19.

Torre-Amione G, Tuetken R, Rowley D . Powerful immunosuppression mediated by interleukin 2-activated, nonantigen-specific, or H-2-restricted THY-1+ CD8+ cells. Cell Immunol. 1989; 124(1):50-63. DOI: 10.1016/0008-8749(89)90111-1. View

20.

Bodmer S, Strommer K, Frei K, Siepl C, Tribolet N, Heid I . Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol. 1989; 143(10):3222-9. View